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Abstract 
Background: To assess the effect of fidaxomicin and vancomycin on Clostridium difficile toxins and correlation with 
clinical and microbiologic outcomes.
Methods: Hospitalized patients with C. difficile infection were randomly assigned a 10-day course of fidaxomicin or 
vancomycin. Stool samples collected at baseline (day 0), mid-therapy (days 3–5), end of therapy (days 10–13) and 
follow-up (days 19–38) were assessed for quantity of toxins A and B as well as spore and vegetative cells counts. Cor-
relation of toxins concentrations with microbiologic and clinical findings were evaluated.
Results: Among 34 patients 12 had detectable toxin concentrations at baseline seven were randomized to fidax-
omicin and five to vancomycin. Overall both fidaxomicin and vancomycin resulted in drop of both toxins concentra-
tions by midpoint of therapy. The drop in toxin A concentrations was maintained up to the follow-up period with 
fidaxomicin but not with vancomycin even in patients who developed recurrence. Patients who developed recur-
rence in the fidaxomicin group had lower concentrations of toxin B versus the recurrence patient of vancomycin 
group. Presence of vegetative cells and spores was significantly linked with high toxin A (P = 0.003 and <0.001 respec-
tively) and toxin B (P = 0.007 and <0.001 respectively) concentrations across time points. Toxin B concentrations but 
not A significantly correlated with stool consistency (P < 0.001) and frequency (P = 0.05).
Conclusions: Fidaxomicin was associated with sustained reduction of both toxins up to 30 days post therapy versus 
vancomycin. Multiple clinical or microbiologic observations were correlated with toxin A or B concentrations.
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Background
Clostridium difficile is a Gram-positive, anaerobic, 
spore-forming, organism that produces two toxins, A 
and B, which represent the major virulence factors of 
the organism [1]. C. difficile infection (CDI) results pri-
marily from the effects of these toxins on the intestine 
causing fluid accumulation, epithelial inflammation, diar-
rhoea, pseudomembranous colitis, and death in severe 
cases [2–4]. The therapeutic goal for the management 
of CDI is to administer antimicrobials that are active 
against the pathogen, thereby reducing the bacterial bur-
den and production of toxins A and B [5]. However, the 
decrease of bacterial burden and toxin quantity based 
on choice of therapy is poorly understood. A previously 
conducted in vitro study found that fidaxomicin but not 
vancomycin or metronidazole inhibited the production 
of C. difficile toxins A and B [6]. The objective of our cur-
rent pilot investigation was to assess the in vivo effect of 
fidaxomicin and vancomycin on C. difficile toxin A and B 
quantity and assess for clinical correlations.
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Methods
Patients and samples
From October 2012 through December 2014, patients 
admitted to Hartford Hospital, Hartford, CT, USA with 
CDI confirmed by PCR (GeneXpert®, Cepheid, Inc.; Sun-
nyvale, CA) were screened for an open-label, randomized 
study comparing the effects of fidaxomicin and vancomy-
cin on microbiologic outcomes of CDI [7]. Less than 24 h 
of anti-CDI treatment was allowed prior to entry into the 
study. Patients were treated orally for 10 days with either 
fidaxomicin 200  mg every 12  h or vancomycin 125  mg 
every 6 h. Stool samples were collected at baseline (before 
therapy initiation, day 0), midpoint of therapy (days 3–5), 
end of therapy (days 10–13) and follow-up (days 19–38). 
The study protocol was approved by the Hartford Hospi-
tal Institutional Review Board, and all patients provided 
written, informed consent prior to entry into the study.
Quantification of C. difficile toxins
C. difficile toxins A and B were quantified separately by 
C. difficile toxin A or B quanti kit (tgcBiomics GmbH, 
Germany) using sandwich enzyme-linked immunoas-
say (ELISA) [8]. Stool samples (50  μL if liquid/semiliq-
uid or 50  mg if solid) were diluted at a ratio of 1:10 by 
dilution buffer (450  μL) provided with the kit. Samples 
were then homogenized with disposal pipetting suction 
and ejection or vortexing followed by centrifugation at 
2500×g for 5 min. One hundred μL of clean supernatant 
was pipetted and poured into the microtiter plate well 
for toxin A or B analysis. Plates were read by Synergy HT 
microplate reader (BioTek Instruments, Inc., Winooski, 
VT) and measured optical density was analysed into 
respective concentration values by Gen5 software ver-
sion1.09 (BioTek Instruments, Inc., Winooski, VT). The 
lower and upper limits of detection of the assay were 0.3 
and 80 ng/mL, respectively, for both toxin A and B.
Quantification of C. difficile bacterial counts
Quantification of C. difficile spores and vegetative cells was 
undertaken as previously described [9]. In brief, samples 
were cultured within 24 h of collection and colony form-
ing units (CFU) were manually counted after incubation at 
37 °C. Two aliquots of the sample were prepared; one was 
plated after treatment with ethanol in order to kill vegeta-
tive cells and keep spores, while the other was plated prior 
to ethanol treatment to keep both the spores and vegeta-
tive cells. Subtracting the number of spore CFUs in the 
ethanol-treated plate from the total number of CFUs in the 
untreated plate equalled the count of vegetative cells CFUs.
Definitions
CDI clinical cure was defined as normalization of stool 
consistency and reduction of stool frequency to less than 
three unformed stools per day by day 10 of therapy. Clini-
cal failure was defined as worsening of CDI with subse-
quent need for additional treatment beyond 10 days or a 
change in antibiotic therapy. Recurrence of CDI (defined 
as the presence of C. difficile along with clinical signs 
and symptoms of CDI) during the follow-up period was 
considered clinical failure for that time period. Asympto-
matic colonization assessed during the follow-up period 
was defined as presence of C. difficile in stool without 
clinical symptoms of CDI. Stool consistency was visually 
determined for each collected sample using Bristol stool 
scale [10]. Stool frequency was determined based on the 
number of bowel movements over the last 24 h prior to 
sample collection.
Analysis
To be included in the analysis, a stool sample with detect-
able toxin A or B at baseline was required. Differences 
between the fidaxomicin and vancomycin groups in 
terms of reduction in toxins concentrations from base-
line compared to each subsequent sampling time were 
numerically described in the overall population of each 
treatment group, as well as after stratification for clinical 
cure and failure at end of therapy and follow-up. Spear-
man correlation (rs) was used to assess the correlation 
between vegetative cells to toxins concentrations, as well 
as to assess the correlation of the latter to stool consist-
ency and frequency. A P value of 0.05 was considered sta-
tistically significant. All analyses were conducted using 




Thirty four patients with CDI were enrolled during the 
study time period (Fig.  1). Of these 34 patients, 12 had 
detectable concentrations of toxin A or B in their base-
line stool samples. Of these 12 patients, seven were 
among the fidaxomicin group and five in the vancomycin 
group. Patients given fidaxomicin or vancomycin were 
similar with regards to baseline characteristics (P  >  0.3 
for all comparisons) (Table 1).
Among the 7 patients given fidaxomicin, one withdrew 
consent prior to end of therapy while the remaining six 
experienced clinical cure. Of these six patients, two expe-
rienced CDI recurrence during the follow-up period. Of 
the remaining four patients given fidaxomicin, 2 were 
asymptomatically colonized with C. difficile during the 
follow-up period. Among the 5 patients given vancomy-
cin, three experienced clinical cure. Of these 3 patients, 
one experienced CDI recurrence during the follow-up 
period. Of the remaining two patients, one was lost to 
follow-up and the other remained in remission and was 
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non-colonized with C. difficile. Thus, in total 9 of 12 were 
clinically cured at end of therapy, 5 of 9 patients had a 
sustained clinical cure at follow-up while 3 of 9 experi-
enced CDI recurrences.
Change in stool C. difficile toxin A and B concentrations 
based on receipt of fidaxomicin or vancomycin
Baseline and subsequent concentrations of toxins A 
and B at each sampling time stratified by treatment 
with fidaxomicin or vancomycin are shown in Table  2. 
Figures  2 and 3 illustrate concentrations of toxins A 
and B throughout the duration of the study in individ-
ual patients. Proportion of samples with any detectable 
toxin in the whole patient population decreased from 
100  % at baseline to 33  % at the mid-point evaluation, 
11  % at the end of therapy, and 37  % at the follow-up 
evaluation.
Overall, a decrease in both toxin A and B were 
observed for patients given both fidaxomicin and vanco-
mycin by days 3–5 (midpoint of therapy). Toxin A con-
centrations remained low for patients given fidaxomicin, 
but not vancomycin through the follow-up period includ-
ing two patients who developed CDI recurrence (subjects 
5 and 12; Fig. 2a, b). Toxin B concentrations increased at 
follow-up in patients with CDI recurrence in both fidax-
omicin- (subjects 5 and 12) and vancomycin-treated 
(subject 3) groups (Fig. 3a, b).
Toxin A and B concentrations and clinical outcomes: 
clinical cure
Toxins concentrations were compared between the two 
groups with respect to clinical outcomes at end of ther-
apy and follow-up (Table 3). Within the group of patients 
who were cured by the end of therapy, both fidaxomicin 
and vancomycin were associated with low concentrations 
of toxin B at midpoint versus the failed patients (subjects 
2 and 10) while toxin A concentrations were low at mid-
point for all patients regardless of end of therapy outcome.
CDI recurrence
Low concentrations of toxins A and B were observed in 
the fidaxomicin group patients who remained in remis-
sion at follow-up and those who relapsed compared with 
the concentrations observed in the patient who relapsed 
in the vancomycin group (Table 2). This difference primar-
ily arose from the reduction in toxins concentrations in 
the relapsed patients, where the two patients who initially 
received fidaxomicin had very low concentrations of toxin 
A (subjects 5 and 12), while the patient who previously 
received vancomycin had a concentration of 70.8  ng/mL 
(subject 3). Mean toxin B concentration in the fidaxomicin 
patients who experienced CDI recurrence was lower than 
the concentration measured in the follow-up sample from 
the patient who was initiated on vancomycin and later 
relapsed. Of note, the follow up stool sample of subject 5 
Fig. 1 Flowchart of patients included in the study. CDI Clostridium difficile infection
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was collected within 3 days of initiating the treatment for 
the recurrent infection, while that of subject 12 was col-
lected prior to the initiation of therapy. Both patients were 
treated with a combination therapy of vancomycin and 
metronidazole. The follow up stool sample of subject 3 was 
collected within 24 h of initiating therapy with vancomycin. 
Both colonized and non-colonized patients who remained 
in remission at follow-up in the fidaxomicin group (sub-
jects 29 and 33) did not have detectable concentrations of 
either toxin in their stools.
Correlation of stool and microbiologic characteristics 
with C. difficile toxin concentrations
When the correlation between faecal bacterial load of C. 
difficile was studied with toxins A and B concentrations at 
all time points combined, significant positive correlation 
was observed with both toxins in the presence of vege-
tative cells (rs = 0.5, P = 0.003, for toxin A and rs = 0.3, 
P = 0.007, for toxin B). Moreover, toxin B, but not toxin 
A, was significantly associated with more loose stools 
(rs = 0.5, P < 0.001, versus rs = 0.3, P = 0.07). Addition-
ally, toxin B was weakly associated with more frequent 
bowel movements (rs = 0.3, P = 0.05) while toxin A did 
not demonstrate such correlation (rs = 0.2, P = 0.2).
Discussion
While antibiotics with activity against C. difficile are the 
mainstay of therapy for CDI, agents with additional anti-
toxin effects may provide an added benefit in the man-
agement of the disease. In an attempt to assess the effect 
Table 1 Baseline characteristics of patients infected with Clostridium difficile who had detectable toxins concentrations 
in their baseline stools
a CDI diagnosis in patients who had not been discharged from a healthcare facility in the previous 12 weeks [11]
Demographic Fidaxomicin Vancomycin P value
N = 7 N = 5
Age, years 68 ± 18 73 ± 12 0.87
Female, n (%) 3 (43 %) 3 (60 %) 1
Community-acquired CDIa, n (%) 4 (57 %) 2 (40 %) 1
BI/NAP1/027 strain, n (%) 5 (71 %) 2 (40 %) 1
Average unformed stool per day, n 6 6 1
Patients by bristol stool score, n (%) 0.4
 7 5 (71 %) 3 (60 %)
 6 0 1 (20 %)
 ≤5 2 (29 %) 1 (20 %)
Baseline toxin A concentration (ng/mL) 0.31 [0.31–80] 3.99 [2.32–63.47] 0.53
Baseline toxin B concentration (ng/mL) 42.2 [23.62–80] 0.31 [0.31–80] 0.43
Baseline total CFU, log10 CFU/g stool 6.05 ± 2.2 6.8 ± 0.9 0.48
Baseline spores CFU, log10 CFU/g stool 5.44 ± 1.7 5.88 ± 1.24 0.75
Baseline vegetative cells CFU, log10 CFU/g stool 4.85 ± 2.85 6.57 ± 0.9 0.3
Previous therapy within 24 h, n (%) 0.66
 Metronidazole 2 (29 %) 2 (40 %)
 Vancomycin 0 0
 Vancomycin + Metronidazole 3 (42 %) 3 (60 %)
 No therapy 2 (29 %) 0
Table 2 Faecal concentrations of C. difficile toxins A and B stratified by therapy with vancomycin or fidaxomicin
Values represent mean ± standard deviation (proportion of patients with a detectable toxin concentration)
Baseline Mid-point End-of-therapy Follow-up
Toxin A
 Fidaxomicin 34.5 ± 39.4 (42.8 %); n = 3/7 0.7 ± 0.9 (14.3 %); n = 1/7 0.3 ± 0 (0 %); n = 0/6 0.3 ± 0 (0 %); n = 0/6
 Vancomycin 27.1 ± 31.5 (100 %); n = 5/5 0.3 ± 0 (0 %); n = 0/5 19.1 ± 26.6 (33.3 %); n = 1/3 35.5 ± 35.2 (50 %); n = 1/2
Toxin B
 Fidaxomicin 45.5 ± 27.9 (100 %); n = 7/7 4.5 ± 10.2 (14.3 %); n = 1/7 0.3 ± 0 (0 %); n = 0/6 5 ± 8.2 (33.3 %); n = 2/6
 Vancomycin 32.2 ± 39 (40 %); n = 2/5 3 ± 3.2 (60 %); n = 3/5 26.9 ± 37.5 (33.3 %); n = 1/3 25.3 ± 25 (50 %); n = 1/2
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of conventional therapies on the dynamic process of tox-
ins production in vitro, Babakhani and colleagues utilized 
sub-MIC concentrations of fidaxomicin, vancomycin, 
and metronidazole to compare C. difficile toxin produc-
tion without affecting the bacterial growth [6]. Fidax-
omicin was the only agent to inhibit the expression of the 
genes (TcdA and TcdB) that code for the production of 
toxin A and toxin B presumably via its macrolide based 
mechanism of transcription inhibition. This finding may 
explain the observations seen in the current study in 
which fidaxomicin was associated with substantial over-
all reduction of both toxins as opposed to vancomycin in 
patients with CDI. The effect of reducing toxin B concen-
trations by fidaxomicin was also observed by Louie et al. 
[12]. In contrast to their study, which only assessed toxin 
B concentration, we assessed the change in both toxins A 
and B concentrations over time from the start of the CDI 
episode until after 30  days post initiation of anti-CDI 
treatment. We found that fidaxomicin was associated 
with sustained reduction of both C. difficile toxins over 
the course of the disease until the follow-up even in the 
two patients who developed CDI recurrence where they 
maintained undetectable concentrations of toxin A and 
low concentrations of toxin B.
The positive correlation of C. difficile bacterial load 
with toxins concentrations observed in the current 
study is consistent with a finding by Åkerlund et al. [5]. 
This observation helps elucidating the minor effect of 
Fig. 2 Toxin A concentrations (ng/mL) of individual patients in the fidaxomicin (a) and vancomycin (b) groups at each time point. *Only patients 
with detectable toxin B concentration at any point are presented. Subjects 5, 12, and 3 had CDI recurrence; whereas subject 33 had asymptomatic 
colonization
Fig. 3 Toxin B concentrations (ng/mL) of individual patients in the fidaxomicin (a) and vancomycin (b) groups at each time point. *Only patients 
with detectable toxin B concentration at any point are presented. Subjects 5, 12, and 3 had CDI recurrence; whereas subject 33 had asymptomatic 
colonization
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vancomycin on reducing toxins concentrations which 
is presumed to occur through bacterial killing, whereas 
fidaxomicin acts on both the bacteria and the toxin pro-
duction mechanism. Additionally, similar to the find-
ing by Åkerlund et al. we found a significant correlation 
between toxin B concentrations and frequent bowel 
movements aiding the general notion that C. difficile tox-
ins are the major drive of the disease severity.
Although our study included a limited number of 
patients, the use of our unique stool sampling scheme 
combined with toxin concentration determination pro-
vides some novel insight. Notably, we showed that 
fidaxomicin was associated with reduction in the over-
all concentrations of C. difficile toxins up to more than 
30  days post therapy initiation regardless of the clinical 
outcome as compared with vancomycin. Additionally, the 
elimination of C. difficile toxins may also aid in relieving 
the diarrheal symptoms of the disease since their con-
centrations were highly correlated with stool consist-
ency and frequency. For example, the two patients who 
had CDI recurrence who initially received fidaxomicin 
had less frequent and more formed stools compared 
with their counterpart patient who initially treated with 
vancomycin. The study was also limited by the number 
of comparators as looking at the effect of other anti-CDI 
agents, such as metronidazole and rifaximin, may provide 
additional understanding of their effect on C. difficile 
toxins concentrations. Moreover, the current study only 
enrolled patients admitted to the hospital (i.e., patients 
presenting with severe form of the disease). Therefore, 
Table 3 C. difficile toxin A and B concentrations based on clinical outcomes
Values represent mean ± standard deviation (proportion of patients with a detectable toxin concentration)
The lower and upper limits of detection were 0.3 and 80 ng/mL, respectively, for both toxin A and B
CDI Clostridium difficile infection, N/A not applicable
a None of fidaxomicin patients failed therapy at the end of the 10-day treatment course
b In the vancomycin group, one patient experienced sustained cure while one developed CDI recurrence, thus standard deviation is not reported
Period Outcome  
measure
Therapy Baseline Mid-point End-of-therapy Follow-up
End of therapy Cured Fidaxomicin A: 40.2 ± 39.8 (50 %); 
n = 3/6
B: 48.8 ± 28.8 (100 %); 6/6
A: 0.7 ± 1 (0.2 %);  
n = 1/6
B: 5.2 ± 10.8 (0.2 %); 
n = 1/6
A: 0.3 ± 0 (0 %); 0/6
B: 0.3 ± 0 (0 %); 0/6
N/A
Vancomycin A: 28.2 ± 36.6 (100 %); 
n = 3/3
B: 26.9 ± 37.6 (33.3 %); 
n = 1/3
A: 0.3 ± 0 (0 %); n = 0/3
B: 0.8 ± 0.7 (33.3 %); 
n = 1/3
A: 19.1 ± 26.6 (33.3 %); 
n = 1/3
B: 26.9 ± 37.6 (33.3 %); 
n = 1/3
N/A
Failed Fidaxomicina N/A N/A N/A N/A
Vancomycin A: 25.5 ± 21.5 (100 %); 
n = 2/2
B: 40.2 ± 56.3 (50 %); 
n = 1/2
A: 0.3 ± 0 (0 %); n = 0/2
B: 6.4 ± 3.3 (100 %); 
n = 2/2
N/A N/A
Follow-up Sustained cure Fidaxomicin A: 20.2 ± 34.5 (25 %); 
n = 1/4
B: 33.3 ± 22.9 (100 %); 
n = 4/4
A: 0.3 ± 0 (0 %); n = 0/4
B: 0.3 ± 0 (0 %); n = 0/4
A: 0.3 ± 0 (0 %); n = 0/4
B: 0.3 ± 0 (0 %); n = 0/4
A: 0.3 ± 0 
(0 %); 
n = 0/4
B: 0.3 ± 0 
(0 %); 
n = 0/4
Vancomycinb A: 2.2 (100 %); n = 1/1
B: 0.3 (0 %); n = 0/1
A: 0.3 (0 %); n = 0/1
B: 0.3 (0 %); n = 0/1
A: 0.3 (0 %); n = 0/1
B: 0.3 (0 %); n = 0/1
A: 0.3 (0 %); 
n = 0/1
B: 0.3 (0 %); 
n = 0/1
CDI recurrence Fidaxomicin A: 80 ± 0 (100 %); n = 2/2
B: 80 ± 0 (100 %); n = 2/2
A: 1.6 ± 1.3 (50 %); 
n = 1/2
B: 15 ± 14.5 (50 %); 
n = 1/2
A: 0.3 ± 0 (0 %); n = 0/2
B: 0.3 ± 0 (0 %); n = 0/2
A: 0.3 ± 0 
(0 %); 
n = 0/2
B: 14.2 ± 8.5 
(100 %); 
n = 2/2
Vancomycinb A: 2.5 (100 %); n = 1/1
B: 0.3 (0 %); n = 0/1
A: 0.3 (0 %); n = 0/1
B: 1.7 (100 %); n = 1/1
A: 56.7 (100 %); n = 1/1
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conducting a similar study on outpatients may elaborate 
these outcomes in a CDI population who are less sick 
and presenting with mild-to-moderate CDI. Based on the 
results of this study, we conclude that fidaxomicin can be 
considered a viable anti-CDI agent for patients experi-
encing severe form of the disease since it was associated 
with lower concentrations of both C. difficile toxins. A 
study done on a larger patient population can help fur-
ther exploration of this outcome.
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